The Board has also approved plans to invest approximately Rs. 500 crores including cost of land in developing a state-of-the-art, 400-bed super specialty hospital
Investment demonstrates confidence in America’s commitment to science and innovation
Merck Wilmington Biotech will serve as a launch and commercial production facility and the future U.S. home for KEYTRUDA
Delivers robust earnings performance, successfully navigating a dynamic environment
Planned acquisition will strengthen the presence of Merck Healthcare in the United States and expand reach of SpringWorks’ therapeutic innovations to more patients with rare tumors worldwide
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Akums and TNAU will collaborate to strengthen research through shared expertise and innovative agricultural solutions, to foster innovation in formulation development
The 27 greenfield labs across the country ensure timely and accurate reporting
The capital raise will also support debt repayment or prepayment, improving the company's debt-to-equity ratio and overall financial resilience
Subscribe To Our Newsletter & Stay Updated
